Clinical trial · Observational
Nutritional Assessment of Patients With Non-small Cell Lung Cancer Treated With Osimertinib
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Nutritional assessment of patients with non-small cell lung cancer treated with osimertinib. Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases and is a leading cause of morbidity and mortality worldwide. Between 35% and 65% of NSCLC patients experience nutritional problems or malnutrition, which significantly affects their prognosis and quality of life. This study aims to describe the nutritional status and body composition of NSCLC patients treated with osimertinib, an oral tyrosine kinase inhibitor, while also assessing the prevalence of sarcopenia, presarcopenia, and dynapenia. Additionally, we explore the relationship between dose-limiting toxicities (DLTs) and nutritional status, as well as the impact of nutritional status on quality of life using the EQ-5D scale.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small-cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
| Quality of Life | — | UNRESOLVED | — |
| Sarcopenia | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Unic group | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Unic group
- description
- Patients diagnosed with NSCLC undergoing treatment with osimertinib in the Vigo Health Area, who receive pharmaceutical care in the Outpatient Clinics of the Pharmacy Service of the Álvaro Cunqueiro Hospital.
- interventionNames
- Other: Unic group
Primary outcomes (18)
- measure
- Gender
- timeFrame
- Day 0, During the consultation
- description
- Patient gender (Female, Male)
- measure
- Age
- timeFrame
- Day 0, During the consultation
- description
- Patient age in years
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients over 18 years of age. * Patients diagnosed with NSCLC. * Patients undergoing osimertinib treatment who collect their medication at the Pharmacy Outpatient Clinic of the Álvaro Cunqueiro Hospital. * Patients who have consented to participate by signing the informed consent form. Exclusion Criteria: * Patients who have discontinued osimertinib treatment. * Patients currently receiving osimertinib treatment for an indication other than those authorized in the product information (compassionate use). * Patients who do not sign the informed consent form. Withdrawal criteria: \- Revocation of consent to participate in the study by the patient.
References
Publications (0)
Data not yet available